375 related articles for article (PubMed ID: 18594135)
21. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
22. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
[TBL] [Abstract][Full Text] [Related]
23. Management of bleeding disorders in adults.
Peyvandi F; Klamroth R; Carcao M; Federici AB; DI Minno G; Jiménez-Yuste V; Rodriguez Merchán EC
Haemophilia; 2012 May; 18 Suppl 2():24-36. PubMed ID: 22530576
[TBL] [Abstract][Full Text] [Related]
24. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
[TBL] [Abstract][Full Text] [Related]
25. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
26. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
27. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
Bravo MI; Ortiz AM; Costa M; Grancha S; Jorquera JI
Haemophilia; 2016 Jul; 22(4):e341-4. PubMed ID: 27354216
[No Abstract] [Full Text] [Related]
29. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
[TBL] [Abstract][Full Text] [Related]
30. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
Kallas A; Talpsep T
Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
[TBL] [Abstract][Full Text] [Related]
31. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
Gringeri A
Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
[TBL] [Abstract][Full Text] [Related]
32. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
33. Animal models of inhibitors.
Reipert B; Arruda V; Lillicrap D
Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
[TBL] [Abstract][Full Text] [Related]
34. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
35. von Willebrand factor: what is its role in the immune response in haemophilia?
Kaveri S; Mannucci PM; Kurth MH; Ewing N; Kessler CM; Nugent DJ; Gomperts ED
Haemophilia; 2011 Jan; 17(1):e235-8. PubMed ID: 20546026
[No Abstract] [Full Text] [Related]
36. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
Astermark J
Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
[TBL] [Abstract][Full Text] [Related]
37. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
38. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
[TBL] [Abstract][Full Text] [Related]
39. Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis.
Calvez T; Laurian Y; Goudemand J
Blood; 2007 Aug; 110(3):1073-4; author reply 1074-5. PubMed ID: 17644742
[No Abstract] [Full Text] [Related]
40. Animal models to explore mechanisms of tolerance induction to FVIII: SCID mice and SCID-FVIII-KO mice.
Gilles JG; Vanzieleghem B; Saint-Remy JM
Haematologica; 2000 Oct; 85(10 Suppl):103-6; discussion 106-7. PubMed ID: 11187860
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
